EP3615073A1 - Molécules de liaison biologiques - Google Patents
Molécules de liaison biologiquesInfo
- Publication number
- EP3615073A1 EP3615073A1 EP18746104.1A EP18746104A EP3615073A1 EP 3615073 A1 EP3615073 A1 EP 3615073A1 EP 18746104 A EP18746104 A EP 18746104A EP 3615073 A1 EP3615073 A1 EP 3615073A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- binding molecule
- cell
- subset
- cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 title claims abstract description 70
- 238000009739 binding Methods 0.000 title claims abstract description 69
- 108091008875 B cell receptors Proteins 0.000 claims abstract description 105
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 31
- 239000012634 fragment Substances 0.000 claims abstract description 21
- 230000003211 malignant effect Effects 0.000 claims abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 238000011321 prophylaxis Methods 0.000 claims abstract description 3
- 108020003175 receptors Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 24
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 210000004408 hybridoma Anatomy 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000000069 prophylactic effect Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 208000012526 B-cell neoplasm Diseases 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 238000011523 CAR-T cell immunotherapy Methods 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 230000001364 causal effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 22
- 230000009826 neoplastic cell growth Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 72
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 36
- 102000005962 receptors Human genes 0.000 description 30
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 29
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 239000002245 particle Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 208000032839 leukemia Diseases 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 102100035634 B-cell linker protein Human genes 0.000 description 7
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 7
- 101000803266 Homo sapiens B-cell linker protein Proteins 0.000 description 7
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000002637 immunotoxin Effects 0.000 description 6
- 239000002596 immunotoxin Substances 0.000 description 6
- 229940051026 immunotoxin Drugs 0.000 description 6
- 231100000608 immunotoxin Toxicity 0.000 description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 101000840267 Homo sapiens Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 2
- 102000001183 RAG-1 Human genes 0.000 description 2
- 108060006897 RAG1 Proteins 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 108010018324 Surrogate Immunoglobulin Light Chains Proteins 0.000 description 2
- 102000002663 Surrogate Immunoglobulin Light Chains Human genes 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960003347 obinutuzumab Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 description 1
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940127130 immunocytokine Drugs 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Definitions
- the present invention relates to the field of production, identification and selection of antibodies or fragments thereof, as well as their use in the context of the prophylaxis and therapy of cancers, in particular malignant B-cell neoplasms.
- Malignant B-cell neoplasms are commonly referred to as malignant diseases of the hematopoietic or lymphatic system. They include diseases such as leukemia and count in a broader sense to the cancers.
- Leukemias are characterized by a greatly increased formation of dysfunctional precursor cells of the white blood cells, which are also called leukemia cells. These cells spread in the bone marrow, displace there the usual blood formation and accumulate usually also greatly increased in the peripheral blood. They can infiltrate the liver, spleen, lymph nodes and other organs, thereby impairing their function.
- the disruption of blood formation results in a decrease in normal blood components, which may cause anemia due to lack of oxygen-carrying red blood cells, lack of hemostatic platelets, and a lack of mature, functional white blood cells.
- Acute leukemias are life-threatening diseases that, if left untreated, can lead to death within a few weeks to months.
- Chronic leukemias usually run over several years and are often symptom poor in the initial stage.
- AML acute myeloid leukemia
- CML chronic myeloid leukemia
- ALL acute lymphoblastic leukemia
- CLL chronic lymphocytic leukemia
- leukemias are treated as part of chemotherapy.
- Newer forms of therapy are increasingly relying on the use of monoclonal antibodies such.
- GA101 bisnutuzumab
- rituximab and ofatumumab acts as a CD20 antibody and is used to treat chronic lymphocytic leukemia (CLL).
- CLL chronic lymphocytic leukemia
- Other malignant diseases of the hematopoietic or lymphatic system malignant B-cell neoplasms
- lymphomas such as lymphoma.
- Hodgkin's lymphoma and B-cell variants of non-Hodgkin's lymphoma are malignant diseases of the hematopoietic or lymphatic system.
- antibodies to receptors When antibodies to receptors are generated, animals are usually immunized with the receptor (purified, cloned, or as peptide fragments) and hybridomas are generated. These hybridoma cells produce antibodies which are then tested by ELISA or by expressed receptors in cell systems. For this purpose, conventionally established cell lines are used, since only these can be easily cultivated. Antibodies can be generated which bind relatively specifically to a particular receptor type (e.g., anti-IgGl, anti-IgE). However, this often leads to cross-reactions with other receptors or other epitopes.
- a particular receptor type e.g., anti-IgGl, anti-IgE
- BCR antibodies For a therapeutic application of BCR antibodies, it is usually not sufficient to use only one antibody against the BCR in general, since such a broadband use can trigger significant side effects. Rather, it would be desirable to provide an antibody that selectively binds to a receptor that has (pathophysiological) activation, particularly autonomous activation. Such an antibody is not known in the art and a Process for its preparation or production by selection does not exist.
- the object of the present invention is therefore to provide alternative concepts and active ingredients such as, in particular, alternative antibodies for prophylactic and / or therapeutic use, with which the existing problems of the prior art are overcome.
- neoplasia generally refers to a regeneration of body tissue, which is a malignant or malignant manifestation of malignant neoplasia, malignant B-cell neoplasia thus being a malignant and uncontrolled neoplasm of B-cells, although this term applies equally to all B-cell associated cancers such as leukemias and B-cell lymphomas
- a "neoplasia-killing area" can kill neoplasias either as a direct or indirect effect.
- more specific Antibody binds a molecule to the antibody or to a functional fragment of this antibody or other biological binding molecule comprising that antibody or its fragment so as to exert an effect beyond the effect of the binding of the antibody or its fragment.
- a molecule may be selected from the group consisting of an immunotoxin, a cytokine, a chelator, a radioisotope, and combinations thereof.
- biological binding molecules herein are meant, for example, but not limited to, antibodies including fusion proteins
- an antibody is selected from the group consisting of an IgG antibody, an IgM antibody, a humanized IgG antibody, and a human
- Such a binding molecule may also be provided in the form of a functional fragment of the entire antibody, eg as a Fab fragment
- a binding molecule may also comprise other regions, eg for the purpose of killing / killing neoplasms
- such a binding molecule may also be membrane- or cell-like
- One such membrane-bound form of a binding molecule is, for example, the chimeric antigen receptor (CAR) on CAR-T Cells.
- CAR chimeric antigen receptor
- B-cell receptor or B-cell receptor complex The role of the B-cell receptor or B-cell receptor complex (BCR) on the surface of a B-cell is to recognize and bind pathogens, so it can be regarded as a membrane-bound antibody. This binding leads to a conformational change of the BCR, which triggers a signal cascade which ultimately leads to activation of the BCR. Cell leads.
- the BCR is formed in great variety in maturing B cells.
- B cells The development of B cells occurs in humans and in some other mammals in the bone marrow or fetal liver.
- the signals necessary for the development program are obtained from the developing lymphocytes of so-called stromal cells.
- B-cell development the formation of a functioning B-cell receptor (the membrane-bound form of the 'antibody') is of crucial importance. Only with this antigen receptor are mature B cells later able to recognize foreign antigens and bind to hostile structures through the formation of corresponding antibodies.
- the antigen specificity of the receptor is determined by the linkage of certain gene segments. The segments are called V, D and J segments, which is why the process is called V (D) J recombination. These segments, which form the antigen-binding part of the B-cell receptor, rearranged.
- the entire receptor consists of two identical light protein chains and two identical heavy protein chains, with the heavy and light chains each linked by disulfide bridges.
- VDJ recombination first the V, D and J segments of the heavy chain of the B cell receptor are linked, followed by the V and J segments of the light receptor chain. Only when the genes are successfully rearranged, which is referred to as productive gene rearrangement, the cell can go into the next development step.
- B cells that react to endogenous antigens during maturation in bone marrow generally die from apoptosis.
- small amounts of autoreactive cells, including thyroglobulin or collagen can be detected (Abul K. Abbas: Diseases of Immunity in Vinay Kumar, Abul K. Abbas, Nelson Fausto: Robbins and Cotran - Pathology Basis of Disease. 1st edition. Philadelphia 2005, p. 224f).
- BCR Since the process of generating such a BCR is based on a random assembly of gene segments, it may happen that the newly created BCR recognizes unwanted endogenous structures and thus becomes “permanently activated.” To prevent the emergence of such a "permanently active or activated" BCR There are various body protection mechanisms. However, if these are overcome due to a pathological change in the developing B-cell, it may develop into a malignant or even autoimmune manifesting disease.
- an “autonomously active” or “autonomously activated” BCR is a special type of permanently active BCR. While conventional activation proceeds from an external antigen (see above), the autonomously active BCR results from its interaction with membrane structures on the surface of the same cell. For the clinical picture of CLL, an autonomous activation-triggering interaction between BCRs could be shown, which were located adjacent to each other on the surface of the same cell (M. Dmixen-von Minden et al., Nature 2012). Another example of an autonomously active BCR is the pre-BCR, which is expressed during the development of a B cell as a development check. In addition to the interaction of neighboring receptors (BCR: BCR), an interaction between the receptor and a membrane protein (BCR: membrane protein) can lead to an autonomously active or activated BCR.
- BCR neighboring receptors
- BCR membrane protein
- a tumor-specific treatment by a significantly improved treatment success and, thanks to the reduction of undesirable systemic effects, a markedly increased therapeutic success is characterized.
- the present invention provides biological binding molecules in the form of antibodies or functional fragments thereof and a method for producing (identifying and selecting) such binding molecules which selectively bind to the modified epitopes of autonomously active membrane-bound immunoglobulins of B-cell neoplasias.
- the biological binding proteins selectively bind to such autonomously active B cell receptors on B cells which occur in immunological (eg autoimmune) diseases and are causally related to them (eg allergies, ulcerative colitis, diabetes mellitus Type 1, multiple sclerosis, psoriasis, rheumatic fever, rheumatoid arthritis, celiac disease).
- immunological eg autoimmune
- psoriasis rheumatic fever
- rheumatoid arthritis celiac disease
- B-cell specific antigens such as CD19, CD22 and CD40
- CD19, CD22 and CD40 were selected as targets of immunotoxins generated with plant toxins such as the ricin A chain and bacterial toxins such as Pseudomonas exotoxin A (PE) (Uckun et al., (1992) Blood 79, 2201-2214 Ghetie et al., (1991), Cancer Res. 51, 5876-5880, Francisco et al., (1995), Cancer Res. 55, 3099-3104).
- PE Pseudomonas exotoxin A
- each individual B-cell progenitor generates its own and almost unique B-cell receptor (BCR) through the rearrangement of individual gene segments.
- BCR B-cell receptor
- subset 2 Two variants (subset 2, subset 4) of the autonomously active BCR are known, which differ from one another with respect to their respective characteristic molecular motif (epitops) (Minici, C. et al., Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukemia, Nature Comm. (2017)). Both variants have different short amino acid sequences that are specific for each of these variants.
- the skilled worker is aware that in addition to the subsets listed, other CLL-B cell receptors are autonomously active.
- the region of subset 2 relevant for the autonomously active functionality of the receptor is characterized by the amino acid sequences KLTVLRQPKA (SEQ ID NO. 1) and VAPGKTAR (SEQ ID NO.
- Range of subset 4 is defined by the amino acid sequences PTIRRYYYYG (SEQ ID NO: 3) and NHKPSNTKV (SEQ ID NO: 4) of the variable part of the heavy chain.
- the sequences used for generating the murine antibodies in the context of immunization for the subsets 2 and 4 are in SEQ ID NOS. 5 and 6 (vHC; LC) and 7 and 8 (vHC; LC), respectively.
- SEQ ID NO. 17 (VSSASTKG), another target sequence or epitope with specificity for the variable part of the heavy chain of a BCR of the subset 4 is given.
- target sequences (epitopes) according to SEQ ID NOS. 3 and 4 represents the sequence according to SEQ ID NO. 17 thus represents another property characteristic of this subset.
- subsets 2 and 4 as two variants of the B cell receptor in critically ill patients is based on the study of numerous case studies and therefore does not indicate that they are not present in a possible variety of other subtypes of the BCR for the two known subtypes characterizing target sequences (epitopes) are present and correlate with a serious disease course.
- the clones identified as potential binding partners in a first step by ELISA were found however, after selection as either nonspecifically binding or not binding to the autonomously active receptor (including SEQ ID Nos. 1 and 2) and therefore had to be discarded.
- the methods used until this finding included not only standard methods such as ELISA and SPR, but also intracellular expression in fibroblasts with an intracellular FACS staining as binding control.
- the binding molecule according to the invention selectively binds to autonomously active or autonomously activated B cell receptors, which are characterized by the presence of structural domains or epitopes (target sequences) and are responsible for the autonomously active or activated state of B cell receptors.
- the selective one Binding behavior of the binding molecule of the invention means that it does not bind to receptors or other membrane structures of B cells that have no structural domain or epitope that are responsible for the autonomously active or activated state of B cells.
- the binding molecule according to the invention does not selectively bind to target sequences of the B cell receptor which are not characteristic of the subset 2 or the subset 4, and in particular to a B cell receptor which does not contain any of the sequences SEQ ID NOS. 1, 2, 3 and / or 4.
- pro- / pre-B cells derived from Triple Knockout (TKO) mice is particularly well-suited to these receptors, despite the difficult handling and costly recovery be expressed and used in a test system for the identification of these receptors.
- the stage of pro- / pre-B cells is naturally designed to carry out the maturation and selection of BCRs, and the cells of this stage are particularly suitable because of their enzyme endowment (chaperones, etc.), even for "difficult" BCR components
- the deletions (knockouts) described below prevent a recombination or the use of the surrogates light chain ("surrogate light chain”) from causing a change in the desired BCR.
- the antibodies suitable for prophylactic and / or therapeutic purposes could be obtained in larger quantities in the form of monoclonal antibodies.
- the binding site of the antibody could be determined (see SEQ ID Nos. 9 and 10).
- Corresponding methods are known to the person skilled in the art and are also commercially available. It is advantageous here to obtain a larger number of hybridoma cells and to select those with the best binding activity (specificity and binding strength / affinity).
- the coding sequence was inserted into an expression plasmid with the DNA of a human antibody sequence to produce a humanized monoclonal antibody with the desired specificity in the usual way of recombination. Because of their unique specificity, these humanized antibodies showed better prophylactic and therapeutic efficacy compared to conventional drugs with relatively few side effects. It will be clear to those skilled in the art that these humanized antibodies can be produced in large quantities by biotechnological means. For the purification of the synthesized antibodies, standardized methods can be used, e.g. Combinations of precipitation, filtration and chromatography, which is well known to those skilled in the art, care should be taken not to denature the antibodies and to detect possible foreign substances such as e.g. To quantitatively remove proteins, pyrogens and toxins.
- the desired antibodies are expressed in systems in which the antibody is glycosylated, such as in particular undergoes a human glycosylation.
- systems are well known to those skilled in the art and include the use of insect cells (S2 cells), mammalian cells (CHO cells), and, most preferably, human cells such as HEK293T type cells.
- the sufficiently purified antibody may in itself be therapeutically effective, provided that it has an isotype which elicits a specific immune response, e.g. an IgG subtype that leads to an immune response against the tumor via Fc receptors.
- the antibody can also be present as a fragment. It is important that the antigen-binding site is present in the fragment, so it is a functional fragment. Such fragments can be e.g. by protease treatment as F (ab) produce fragments. Since these fragments are truncated in the constant part of the antibody, it is advantageous and therefore preferred to insert an effector molecule for killing neoplasms.
- the antibody is provided with a conjugate to enhance its effect.
- This conjugate is an area for killing neoplasms and can kill such neoplasias either as a direct or indirect effect.
- An example of such a conjugate is the binding of ricin to the antibody, wherein its preferably covalent attachment is carried out, for example, by using chemical crosslinkers.
- the antibody can also be used in modified form, for example as a biological binding molecule in the form of a fusion protein with T cell specific activation domains are present.
- T cells are first recovered from the patient's peripheral blood and engineered in vitro to express the CAR on their cell surface. Subsequently, these modified T cells are reintroduced into the patient, thus making CAR T cell immunotherapy feasible (see, eg, N Engl J Med. 2014 Oct 16; 371 (16): 1507-17. Doi: 10.1056 / NEJMoal407222 ).
- the antibody is preferably employed in a composition comprising a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier is a carrier which is physiologically contracted for a patient being treated and which preserves the therapeutic properties of the compound with which it is administered.
- An exemplary pharmaceutically acceptable carrier is physiological saline.
- Other suitable physiologically acceptable carriers and their formulations are known to those skilled in the art and are described, for example, in Remington's Pharmaceutical Sciences (18th ed.), Ed. A. Gennaro, 1990, Mack Publishing Company, Easton, PA).
- a stabilizing salt buffer may be, for example, a phosphate-buffered saline (PBS), as known to those skilled in the art.
- PBS phosphate-buffered saline
- a suitable drying form is, for example, freeze-drying or lyophilization.
- the antibody of the invention having specificity for the autonomously activated BCR (subset-2) in an apharesic system can be used to separate leukemia cells from a blood sample of a patient.
- various methods are suitable for this, as is known to the person skilled in the art.
- the antibodies may be bound to magnetizable particles (beads) (eg Dynabeads).
- the blood is provided with an anticoagulant and brought into contact with the particles outside the body of the patient.
- at least one particle preferably 10 to 100 particles, is used for each tumor cell.
- a particle with a size of, for example, less than 20 ⁇ typically contains several antibodies of the same specificity (number of particles greater than 5000 / ⁇ 1 blood). With the help of magnets, these particles can then be bound before the purified, residual blood is returned to the patient. This therapeutic measure significantly reduces the number of tumor cells in the patient's blood.
- the particles have sizes of more than 20 ⁇ and also have a variety of antibodies per particle (>100,> 1000).
- lymphocytes tumor cells
- These particle / cell conjugates are removed by classical centrifugation as commonly used in apharesis. The times required depend on the nature of the particles and the apparatus and must be determined experimentally.
- both the particle / cell conjugates in particular when using large particles over 20 ⁇ m in diameter
- free particles without cell binding can be separated off with the aid of a fine network of blood.
- Such networks are commercially available, for example, as so-called 'cell trainers'.
- Methods of conjugating the antibodies to the particles are well known to those skilled in the art. Procedural instructions are provided eg by Dynal to their customers. Individual aspects of the present invention will be explained in more detail below with reference to examples.
- the production and identification of antibodies that bind selectively to the modified B cell receptors has been characterized by major and unforeseen problems.
- the generation of the hybridomas was carried out by standard methods.
- the supernatant from the hybridoma groups was pooled and tested for positive binding events by ELISA (soluble B cell receptors on the ELISA plate). Positive pools were isolated and the individual clones tested. Surprisingly, no positive clones were identified in the ELISA.
- the positive ELISA signals of the Poole subsequently turned out to be unspecific bindings.
- the BCR light chain has now been expressed in fibroblasts. This should ensure the correct folding of the protein bearing the motif (epitope) responsible for the autonomic signal. Intracellular FACS analyzes were performed on these cells. No positive clone (antibody) could be identified. For this reason, in another experiment, RAMOS cells (human Burkitt lymphoma cell line) were modified to have functional modified BCRs. This should ensure complete biosynthesis, folding and modification of the BCR.
- the cell's own BCR was deleted by means of CRISPR, and then the "CLL receptor" was reconstituted molecularly (electroporation of CMV vectors) . These cells were used to test positive binding events, again with no positive clone detectable by FACS.
- RAGl and RAG2 form a complex which allows the usual VDJ rearrangement, which is why a knockout of RAGl is an equal-acting agent and thus an alternative to the knockout of RAG2 and is encompassed by the teaching according to the invention.
- the deletion of lambda5 a part of the surrogate light chain, prevents the formation of a pre-BCR. Since the pre-BCR is autonomously active, this would interfere with the detection of an autonomously active receptor. Since a new BCR is cloned into the cell here, a pre-BCR is undesirable, since this one with the desired heavy chain (HC) in conjunction with the unwanted surrogates light chain would appear on the surface and interfere with the selection.
- the knockout of SLP65 an adapter protein of central importance in the BCR signaling pathway, prevents the activation of the
- the knockout of RAG2 or RAG1 and lambda5 is sufficient.
- the activity of the BCR can be measured.
- the method of choice here is the measurement of Ca flux after induction of the SLP65 by means of FACS analysis and the use of a Ca 2+ -dependent dye such as Indo-1. These methods are known to those skilled in the art (see, for example, M. Dschreiben-von Minden et al., Nature 2012.)
- the first two knockouts ensured that only the "BCR of interest" was expressed on the surface
- the inducible SLP65 with which the cells were reconstituted may characterize the function of the expressed BCRs and thus verify the autonomously active state of the BCRs on the surface prior to selection.
- the expression of the BCR was determined by means of anti-IgM and anti-LC antibodies on the FACS. For this purpose, a few cells were taken and stained with 5 ⁇ l antibody in a total volume of ⁇ in PBS. Using these cells as the "target", FACS was now able to identify an antibody that specifically binds to the modified region that is responsible for and is responsible for the autonomous activation of BCR, even though binding to the same type of receptor in RAMOS cells was not successful!
- the cells which carried the "BCR of interest” on the surface were first incubated with the pooled supernatants, and after a few washing steps, the bound antibodies were detected by means of secondary antibodies.TKO cells (TKOs) were used for a specific selection different versions of the "BCR of interest” expressed.
- the selection matrix shown in FIG. 1 is exemplary for the selection of a CLL subset 2 BCR and was used to identify and select positive clones.
- the supernatants of the hybridomas were pooled and measured. The groups that showed binding were singulated and the supernatants of the respective hybridomas tested for binding.
- mice which have a respective knockout for the genes Lambda5, RAG2 and SLP65 (Dlicken von Minden et al., 2012, Nature 489, p309-313).
- the preparation of such mice is known in the art and belongs to the prior art.
- the mice were extracted after their killing the bone marrow of the femurs.
- the cells thus obtained were then cultured under conditions favoring the survival of pro- / pre-B cells (37 ° C, 7.5% CO2, Iscoves medium, 10% FCS, P / S, murine IL7).
- a FACS sorting was performed as a control, the pro / pre-B cells were sorted and then returned to culture.
- the markers used for this purpose are known to the person skilled in the art.
- the corresponding sequences coding for the heavy (HC) and light (LC) chains were synthesized and then each cloned into a CMV promoter-containing expression vectors. These were incorporated by lipofection into the packaging cell line (Phoenix cell line). After a 36 hour incubation, virus supernatant was removed and used for spinfection of TKO cells. Both the work for the recovery of the supernatants and the spinfection of the TKO are widely known methods and known to the skilled person.
- subset-2 B cell receptors were taken from the corresponding literature (see above).
- Exemplary CLL subset 2 VH and complete LC DNA segments were synthesized by a contract manufacturer in a standard procedure. These were then fused with a murine IgGl constant segment by PCR and transformed into a CMV Vector cloned. The sequence of the final vector was confirmed by Sanger sequencing.
- CLL subsets 2 IgG1 For expression of CLL subsets 2 IgG1, a human cellular expression system based on HEK293T cells was used. For transfection, a polyethyleneimine (PEI) based protocol was used. After several passages, the supernatant was pooled and the medium contained in the pooled cell supernatant was purified by means of Protein G columns. The purity and quality of the soluble Subset-2 IgGl was determined by Western blot.
- PEI polyethyleneimine
- the mRNA was isolated from the individual hybridoma clones, from which cDNA was generated and amplified by means of anchor PCR (Rapid Expression Cloning of human immunoglobulin Fab fragments for the analysis of antigenic specificity of B cell lymphomas and anti-idiotype lymphoma vaccination; Osterroth F, alkane 0, Mackensen A, Lindemann A, fish P, Skerra A, Veelken H., J Immunol Methods 1999 Oct 29; 229 (1-2): 141-53).
- CDRs binding sites
- SEQ ID NO. 9 shows the variable part of the heavy chain (HC)
- SEQ ID NO. 10 relate to the variable part of the light chain (LC)
- the marked regions - in the order given - denote CDR 1, 2 and 3.
- SEQ ID NO. 9 (AVA-mAbOl HC)
- Exemplary CLL subset 4 VH and complete LC DNA segments were synthesized by a contract manufacturer in a standard procedure. These were then fused with a murine IgGl constant segment by PCR and cloned into a C V vector. The sequence of the final vector was confirmed by Sanger sequencing.
- CLL subset 4 HC (SEQ ID NO. 7) QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWTWIRQSPGKGLEWIGEINHSGSTTYNPSL KSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGYGDTPTIRRYYYYGMDVWGQGTTVTVSS ASTKGPSVFPLAPSSKSTSGGTA ⁇ LGCLVKDYFPEPVTVSWNSGALTSGVHTFPACLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKC The bold regions indicate the target sequences (epitopes) of the variable part of the heavy chain of the BCR the subset 4, which are responsible for its autonomous active state (see FIG. SEQ ID NOS. 3 and 4).
- CLL Subset 4 LC (SEQ ID NO. 8): DIVMTQSPLSLPVTLGQPASISCRSSQSLVHSDGNTYLNWFQQRPGQSPRRLIYKVSDRDSGV PDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQGTHWPPYTFGQGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK ADYEKHKVYACEVTHQGLSSPVTKS FNRGEC.
- the antibody of the invention having autonomous activated BCR (Subset-2) specificity was used in an apharesic system to separate leukemia cells from a patient's blood sample. Peripheral blood was collected from a patient (EDTA blood from blood collection tubes). The lymphocyte count was determined using a cell counter and yielded 80,000 lymphocytes / ⁇ .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17001167 | 2017-07-07 | ||
EP17001166 | 2017-07-07 | ||
EP18162672.2A EP3424528A1 (fr) | 2017-07-07 | 2018-03-19 | Molécules de liaison biologiques |
PCT/EP2018/068317 WO2019008129A1 (fr) | 2017-07-07 | 2018-07-05 | Molécules de liaison biologiques |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3615073A1 true EP3615073A1 (fr) | 2020-03-04 |
Family
ID=64500047
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18162666.4A Withdrawn EP3424527A1 (fr) | 2017-07-07 | 2018-03-19 | Proces diagnostique |
EP18162672.2A Withdrawn EP3424528A1 (fr) | 2017-07-07 | 2018-03-19 | Molécules de liaison biologiques |
EP18746103.3A Pending EP3615072A1 (fr) | 2017-07-07 | 2018-07-05 | Procédé de diagnostic |
EP18746104.1A Pending EP3615073A1 (fr) | 2017-07-07 | 2018-07-05 | Molécules de liaison biologiques |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18162666.4A Withdrawn EP3424527A1 (fr) | 2017-07-07 | 2018-03-19 | Proces diagnostique |
EP18162672.2A Withdrawn EP3424528A1 (fr) | 2017-07-07 | 2018-03-19 | Molécules de liaison biologiques |
EP18746103.3A Pending EP3615072A1 (fr) | 2017-07-07 | 2018-07-05 | Procédé de diagnostic |
Country Status (5)
Country | Link |
---|---|
US (2) | US11591391B2 (fr) |
EP (4) | EP3424527A1 (fr) |
JP (2) | JP7271532B2 (fr) |
CA (2) | CA3070847A1 (fr) |
WO (2) | WO2019008129A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3424527A1 (fr) * | 2017-07-07 | 2019-01-09 | AVA Lifescience GmbH | Proces diagnostique |
WO2020221463A1 (fr) * | 2019-05-02 | 2020-11-05 | Ava Lifescience Gmbh | Procédé de sélection d'une molécule biologique de liaison |
EP3733709A1 (fr) * | 2019-05-02 | 2020-11-04 | AVA Lifescience | Molécules de liaison biologiques |
JP2022537628A (ja) * | 2019-05-02 | 2022-08-29 | アー・ファウ・アー ライフサイエンス ゲー・エム・ベー・ハー | 生物学的結合分子 |
EP4227321A1 (fr) | 2022-02-10 | 2023-08-16 | AVA Lifescience GmbH | Anticorps contre le recepteur des cellules b de la leucemie lymphoide chronique (llc) utilisées dans le traitement de llc |
WO2023152204A1 (fr) | 2022-02-10 | 2023-08-17 | Ava Lifescience Gmbh | Anticorps ciblant le récepteur des lymphocytes b de la leucémie lymphoïde chronique (llc) destinés à être utilisés dans le traitement de llc |
WO2024023124A1 (fr) * | 2022-07-25 | 2024-02-01 | Ava Lifescience Gmbh | Récepteurs antigéniques chimériques humanisés ciblant le récepteur de lymphocytes b de la leucémie lymphoïde chronique et leurs utilisations |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
SG11201405130UA (en) | 2012-02-24 | 2014-11-27 | Stemcentrx Inc | Anti sez6 antibodies and methods of use |
WO2014179714A1 (fr) * | 2013-05-03 | 2014-11-06 | The Board Of Regents Of The University Of Texas System | Génération de vaccins peptoïdes |
SG11201601424PA (en) * | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions |
EP3424527A1 (fr) * | 2017-07-07 | 2019-01-09 | AVA Lifescience GmbH | Proces diagnostique |
-
2018
- 2018-03-19 EP EP18162666.4A patent/EP3424527A1/fr not_active Withdrawn
- 2018-03-19 EP EP18162672.2A patent/EP3424528A1/fr not_active Withdrawn
- 2018-07-05 US US16/625,756 patent/US11591391B2/en active Active
- 2018-07-05 CA CA3070847A patent/CA3070847A1/fr active Pending
- 2018-07-05 US US16/625,754 patent/US11634487B2/en active Active
- 2018-07-05 EP EP18746103.3A patent/EP3615072A1/fr active Pending
- 2018-07-05 EP EP18746104.1A patent/EP3615073A1/fr active Pending
- 2018-07-05 JP JP2020522786A patent/JP7271532B2/ja active Active
- 2018-07-05 CA CA3070848A patent/CA3070848A1/fr active Pending
- 2018-07-05 JP JP2020522785A patent/JP7239575B2/ja active Active
- 2018-07-05 WO PCT/EP2018/068317 patent/WO2019008129A1/fr unknown
- 2018-07-05 WO PCT/EP2018/068316 patent/WO2019008128A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP3615072A1 (fr) | 2020-03-04 |
US11591391B2 (en) | 2023-02-28 |
US20200209246A1 (en) | 2020-07-02 |
JP2020527727A (ja) | 2020-09-10 |
WO2019008128A1 (fr) | 2019-01-10 |
JP7271532B2 (ja) | 2023-05-11 |
JP7239575B2 (ja) | 2023-03-14 |
JP2020526590A (ja) | 2020-08-31 |
WO2019008129A1 (fr) | 2019-01-10 |
US11634487B2 (en) | 2023-04-25 |
EP3424527A1 (fr) | 2019-01-09 |
US20200199225A1 (en) | 2020-06-25 |
EP3424528A1 (fr) | 2019-01-09 |
CA3070847A1 (fr) | 2019-01-10 |
CA3070848A1 (fr) | 2019-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3615073A1 (fr) | Molécules de liaison biologiques | |
DE69128253T2 (de) | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen | |
DE69426743T2 (de) | Bispezifische Auslösemoleküle, die das Lymphozytantigen CD2 und Tumorantigene erkennen | |
DE69605181T3 (de) | Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern | |
DE69531679T2 (de) | Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper | |
DE3853636T3 (de) | Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden. | |
DE69100768T2 (de) | CD25-bindende Moleküle. | |
DE60226036T9 (de) | ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT | |
DE69330523T3 (de) | Immunoglobuline ohne leichte ketten | |
DE69518919T2 (de) | Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung | |
DE69233482T2 (de) | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen | |
DE69019447T2 (de) | Hund-Maus-Heterohybridoma und für die konstante Region von Hunde-Immunglobulinen kodierendes Genfragment. | |
DE69126526T2 (de) | Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen | |
EP2480574A2 (fr) | Anticorps anti-cd33 et leur utilisation pour l'immunociblage dans le cadre du traitement de troubles associés à cd33 | |
DE69126607T2 (de) | Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper | |
DE69938451T2 (de) | Fas peptide und antikörper zur modulierung von apoptosis | |
DE69333039T2 (de) | Monoklonaler antikörper gegen ein humanes mdr1-gen produkt, das eine resistenz gegen verschiedene medikamente erzeugt und seine verwendung | |
WO2020221466A1 (fr) | Molécules de liaison biologiques | |
DE60223688T2 (de) | Verfahren zur behandlung von multiplem myelom | |
DE10050935A1 (de) | Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen | |
EP3505536A1 (fr) | Anticorps contre l'antigène des cellules souches prostatiques et leur utilisation | |
EP3899536B1 (fr) | Procédé de sélection de molécules de liaison biologiques | |
DE60208534T2 (de) | Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle | |
DE10210427A1 (de) | Humaner monoklonaler Antikörper | |
DE69635161T2 (de) | Rekombinante hetero-multimerische proteine von dem alpha-beta c4 bp typ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191126 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210618 |
|
19A | Proceedings stayed before grant |
Effective date: 20230512 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AVA LIFESCIENCE GMBH |